- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Strategies To Optimize Patient Outcomes In Bipolar I Disorder: The Role Of Long-Acting Injectable Antipsychotics

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Strategies To Optimize Patient Outcomes In Bipolar I Disorder: The Role Of Long-Acting Injectable Antipsychotics
This is a Virtual Event for PsychU members in Illinois, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota and Wisconsin.
In this presentation, the objectives are to:
- Understand the impact of mood episode recurrence in bipolar I disorder on patient functioning and clinical outcomes
- Discuss risk factors for mood episode recurrence, including nonadherence, in patients with bipolar I disorder
- Review management strategies, including long-acting injectable antipsychotics (LAIs), to optimize patient outcomes in bipolar I disorder

Heather Fields, PharmD, MPH, BCACP (OPDC)
Medical Science Liaison

Pam Wolf, PharmD
Senior Medical Science Liaison
Heather Fields, PharmD, MPH, BCACP and Pam Wolf, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)